UK Herceptin Biosimilar Market Analysis

UK Herceptin Biosimilar Market Analysis


$ 3999

UK herceptin biosimilar market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 – 2030. The market grows as a result of increased research and development as well as rising public knowledge of cancer treatments. Additionally, rising healthcare costs and the existence of innovative pipeline products create an opportunity for market expansion. Some of the key players in this market are Mylan N.V., Amgen Inc., Mabion S.A., AryoGen Biopharma, Genor Biopharma, Celltrion Inc., Gedeon Richter Plc, The Instituto Vital Brazil, F. Hoffmann-La Roche AG, and Biocon.

ID: IN10GBPH301 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Saloni Shah

Buy Now

UK Herceptin Biosimilar Market Analysis Summary

UK Herceptin Biosimilar Market is valued at around $51 Mn in 2022 and is projected to reach $213.5 Mn by 2030, exhibiting a CAGR of 19.6% during the forecast period 2023-2030.

Trastuzumab, often known as herceptin, is a very potent targeted medication used to treat HER2 positive breast cancer. It has completely changed how this aggressive form of cancer is treated, increasing survival rates and giving many sufferers hope. A noteworthy advance in recent years has been the release of herceptin biosimilars, which provide comparable therapeutic advantages while improving accessibility and price. Similar to the original Herceptin, Herceptin biosimilars are precisely made to target HER2 positive breast cancer cells. They function by attaching to the HER2 receptor and preventing cancer cells from proliferating and spreading. Although the structure and mode of action of Herceptin biosimilars are identical to those of the reference medication, they are made by many firms, increasing market rivalry. The market grows as a result of increased research and development as well as rising public knowledge of cancer treatments. Additionally, rising healthcare costs and the existence of innovative pipeline products create an opportunity for market expansion. The global Herceptin Biosimilar market’s major key players are Mylan N.V., Amgen Inc., Mabion S.A., AryoGen Biopharma, Genor Biopharma, Celltrion Inc., Gedeon Richter Plc, The Instituto Vital Brazil, F. Hoffmann-La Roche AG, and Biocon.

Market Dynamics

Market Growth Drivers

Cost-effectiveness, patent expiration, market competition, rising demand for HER2-positive breast cancer treatments, a supportive regulatory environment, healthcare systems' efforts to contain costs, market expansion, and a global focus are some of the factors driving the herceptin biosimilar therapeutic market. These elements work together to support the development and acceptance of herceptin biosimilars as a patient-friendly therapeutic option.

Market Restraints

Regulations governing the approval of biosimilars are strict and may involve lengthy clinical trials and comparisons to the reference product. Some companies are hindered from pursuing the development of herceptin biosimilars because of the time- and money-consuming nature of these regulatory hurdles thereby acting as restraints for herceptin biosimilar market.

Competitive Landscape

Key Players

  • Amgen Inc.
  • Mylan N.V. (now Viatris Inc.)
  • Pfizer Inc.
  • Samsung Bioepis
  • Merck & Co., Inc. (known as MSD outside the United States and Canada)
  • Teva Pharmaceutical Industries Ltd.
  • Coherus BioSciences
  • Biocon Limited
  • BioXpress Therapeutics SA
  • Fresenius Kabi USA

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Herceptin Biosimilar Market Segmentation

By Application

  • Breast cancer
  • Colorectal cancer
  • Leukaemia
  • Lymphoma
  • Others

By Dosage

  • 150mg/single-dose vial
  • 420mg/multidose vial.

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up